Insulin Preservation for Type I Diabetes
(Ivanhoe Newswire) – The latest research from Indiana University studied the effect of a T1DAL trial to question if an alefacept protein would preserve beta cells in the pancreas.
Dr. Mark Rigby and a team of researchers gathered 49 type 1 diabetes patients to test the study. The patients were divided between two groups; alefacept and placebo recipients. After two 12 week courses, the two hour C-peptide results did not show a different response between the placebo and treatment groups. The four hour C-peptide response showed an increase of insulin and a decrease in hypoglycemic events in the alefacept after 12 months.
"The T1DAL study is the first to use an agent to specifically deplete the cells which attack the pancreas in type 1 diabetes, the memory and effector T cells. We also found that regulatory T cells are not depleted with this therapy, suggesting that immune re-education can take place," quoted by Dr. Rigby.
For more information, go to: http://www.thelancet.com/journals/landia/article/PIIS2213-8587%2813%2970111-6/abstract
SOURCE: The Lancet Diabetes & Endocrinology, September 2013
Click Here for a free weekly email with Ivanhoe's latest Medical Breakthroughs.